Rosen Law Firm sets Aug. 10 deadline in ADMA Biologics securities case
Rosen Law Firm says investors who bought ADMA Biologics shares during the stated class period may seek lead-plaintiff status in a securities class action by Aug. 10, 2026.
Rosen Law Firm said Aug. 1, 2026, that investors in ADMA Biologics, Inc. may seek to lead a securities class action tied to shares bought between Aug. 9, 2024, and March 25, 2026.
The notice says anyone who wants to serve as lead plaintiff must move the court by Aug. 10, 2026. Rosen described a lead plaintiff as a representative party that acts on behalf of other class members in directing the litigation.
The notice says the class action has already been filed and that investors who purchased ADMA Biologics securities during the stated period may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket fees or costs.
According to the notice, the lawsuit alleges defendants made materially false and/or misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing used to create an appearance of revenue and inadequate internal controls. It also says the suit claims statements about ADMA Biologics’ business, operations and prospects lacked a reasonable basis.
The notice says investors suffered damages when the true details entered the market. It does not provide court docket details, the names of defendants, or independent verification of the allegations.
Rosen Law Firm identified itself in the notice as a global investor rights law firm focused on securities class actions and shareholder derivative litigation. The firm said investors can join the class action through its website, by phone or by email.
What happens next is set by the Aug. 10 deadline for any investor seeking to ask the court to appoint them lead plaintiff. The notice does not say when the court will hear the request.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.